Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Premenopausal Breast Cancer × Leuprolide × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 146 Breast Neoplasms 20 Neoplasms 9 Leiomyoma 8 Polycystic Ovary Syndrome 5 Adenocarcinoma 3 Salivary Gland Neoplasms 2 Rare Diseases 2 Prostate Adenocarcinoma 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Breast Neoplasms, Male 2 Uveal Melanoma 1 Uterine Neoplasms 1 Urogenital Neoplasms 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Sleep Apnea, Obstructive 1 Skin Neoplasms 1 Skin Diseases 1 Sexual Dysfunction, Physiological 1 Salivary Gland Neoplasm Duct 1 Respiratory Tract Diseases 1 Recurrence 1 Puberty, Precocious 1 Prostatic Diseases 1 Primary Dysautonomias 1 Premenopausal Breast Cancer 1 PSA Level Greater Than Two 1 Obesity, Morbid 1

Interventions

pembrolizumab 1 exemestane 1 Tamoxifen 1 Surgical Procedures, Operative 1 Leuprolide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02990845 2023-02-22

PEER

National Taiwan University Hospital

Phase 1/2 Terminated

Premenopausal Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡